Assertio to Be Acquired by Garda Therapeutics in $125.1 Million All-Cash Deal Assertio Holdings, Inc. has announced a definitive agreement to be acquired by Garda Therapeutics in an all-cash transaction valued at approximately $125.1 million, marking the culmination of a…
Healthpeak Properties, Inc. Announces Q1 2026 Earnings Release and Investor Call Details Healthpeak Properties, Inc., a prominent real estate investment trust (REIT) specializing in properties that support healthcare discovery and delivery, has officially announced the schedule for its first quarter…
Swisslog Healthcare Welcomes Boulder Chamber Manufacturing Group to Its Facility Swisslog Healthcare, a leading provider of pharmacy and transport automation solutions, recently hosted the Boulder Area Manufacturing Sector Partnership’s first quarterly meeting of 2026 at its Broomfield facility. The event…
Compass Pathways plc Confirms Participation in Needham Virtual Healthcare Conference 2026 Compass Pathways plc has announced its participation in an upcoming major investor-focused healthcare event, underscoring its continued commitment to engaging with the financial community and increasing awareness of its…
Veradigm Strengthens Leadership with Appointment of Christian Greyenbuhl as Chief Financial Officer Veradigm Inc. (OTCMKTS: MDRX), a prominent provider of clinical, financial, and data-driven solutions designed to support independent healthcare practices, has announced the appointment of Christian Greyenbuhl as its…
Endospan achieves FDA Approval for NEXUS® Aortic Arch Stent Graft System, Expanding Minimally Invasive Options for High-Risk Patients Endospan, a privately held medical device company based in Tel Aviv, Israel, has reached a significant regulatory milestone with the approval of…
Systane Partners with Toronto Blue Jays to Spotlight Dry Eye Awareness in Canada In a move that blends healthcare awareness with the excitement of professional sports, Alcon has announced a new partnership between its leading eye care brand Systane® and…
GenSight Biologics Reports Q1 2026 Cash Position and Early Access Program Revenue Update GenSight Biologics, a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies targeting retinal neurodegenerative diseases and central nervous system disorders, has reported its…
InterVene Reaches Key Milestone with 30 Procedures Using Recana Thrombectomy System InterVene, Inc., a privately held medical device company focused on advancing interventional solutions for venous disease, has announced a significant clinical milestone: the successful completion of 30 procedures using…
Stoke Therapeutics Strengthens Board with Appointment of Dr. Clare Kahn Stoke Therapeutics, Inc., a biotechnology company focused on transforming the treatment landscape for genetic diseases, has announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. The addition…